Join to View Full Profile
1 Medical Center DrLebanon, NH 03756
Phone+1 603-650-5747
Fax+1 210-257-1428
Dr. Curiel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 1995 - 1997
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1986 - 1990
Yale-New Haven Medical CenterInternship, Internal Medicine, 1985 - 1986
Duke University School of MedicineClass of 1982
Certifications & Licensure
NH State Medical License 2022 - 2026
CO State Medical License 1991 - 2025
TX State Medical License 2000 - 2024
LA State Medical License 2001 - 2008
CT State Medical License 1985 - 1987
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer Start of enrollment: 2007 Feb 01
- Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors Start of enrollment: 2012 Jun 01
- A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer Start of enrollment: 2009 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsBotensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy.Dhan Chand, David A Savitsky, Shanmugarajan Krishnan, Gabriel Mednick, Chloe Delepine
Cancer Discovery. 2024-12-02 - 1 citationsTumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors.Clare E Murray, Anand V R Kornepati, Carlos Ontiveros, Yiji Liao, Bárbara de la Peña Avalos
Molecular Cancer. 2024-10-30 - 17 citationsBotensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial.Andrea J Bullock, Benjamin L Schlechter, Marwan G Fakih, Apostolia M Tsimberidou, Joseph E Grossman
Nature Medicine. 2024-09-01
Journal Articles
- Suppressive IL-17A+Foxp3+ and Ex-Th17 IL-17AnegFoxp3+ Treg Cells Are a Source of Tumour-Associated Treg CellsRobert P Edwards, Tyler Curiel, Sara Berkey, David L Bartlett, Kunle Odunsi, Nature
Press Mentions
- Suppressive IL-17A+Foxp3+ and Ex-Th17 IL-17AnegFoxp3+ Treg Cells Are a Source of Tumour-Associated Treg CellsMarch 14th, 2020
Chutes & Ladders—Biogen Executive Kress Takes over the Reins of SyntimmuneJanuary 5th, 2018
Agenus Announces Key Leadership to Advance Combination Trials for Planned BLA FilingsJanuary 4th, 2018
Grant Support
- Adipocyte PD-L1 in the Breast Tumor MicroenvironmentGEORGE WASHINGTON UNIVERSITY2024–2029
- Melanocyte PDL1 control of UVB-induced IFN-IDARTMOUTH-HITCHCOCK CLINIC2024–2029
- Melanocyte PDL1 control of UVB-induced IFN-IDARTMOUTH-HITCHCOCK CLINIC2024–2029
- Melanocyte PDL1 control of UVB-induced IFN-IDARTMOUTH-HITCHCOCK CLINIC2024–2029
- Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatmentsDARTMOUTH-HITCHCOCK CLINIC2022–2028
- Senior LeadershipNational Cancer Institute2009–2011
- Planning And EvaluationNational Cancer Institute2009–2011
- DevelopmentalNational Cancer Institute2009–2011
- Career DevelopmentNational Cancer Institute2009–2011
- Cancer Prevention And Population SciencesNational Cancer Institute2009–2011
- AntibodyNational Cancer Institute2009–2011
- AdministrationNational Cancer Institute2009–2011
- Phase II Trial Of Ontak To Treat Ovarian Cancer Under B*Food And Drug Administration2007–2010
- A Novel MAPK Family In T. GondiiNational Institute Of Allergy And Infectious Diseases2006–2010
- Plasmacytoid Dendritic Cell Behavior In Ovarian CancerNational Cancer Institute2007–2009
- CXCR4/SDF-1 Interactions In Ovarian Cancer PathogenesisNational Cancer Institute2007
- SAN Antonio Cancer InstituteNational Cancer Institute2005–2007
- A Phase II Trial Of Intravenous Ontak To Treat Epithelial Ovarian Cancer FIGONational Center For Research Resources2006
- Phase II Trial Of Ontak To Treat Ovarian Cancer Under B*Food And Drug Administration2006
- A Novel MAPK Family In T. GondiiNational Institute Of Allergy And Infectious Diseases2005–2006
- Plasmacytoid Dendritic Cell Behavior In Ovarian CancerNational Cancer Institute2005–2006
- Phase I/II Dose De-Escalation Trial Of Intravenous Ontak In Patients With CancerNational Center For Research Resources2004–2006
- CXCR4/SDF-1 Interactions In Ovarian Cancer PathogenesisNational Cancer Institute2004–2006
- Dendritic Cell-Mediated Anti-Tumor ImmunityNational Center For Research Resources2003–2006
- Targeting SIV Nef Directly To Dendritic CellsNational Center For Research Resources2005
- Dendritic Cell Targeted Hepatitis C Virus ImmunotherapyNational Institute On Drug Abuse2003
- Dc-Induced Hiv-Specific T Cell ImmunityNational Institute Of Allergy And Infectious Diseases2001
- Dc-Induced Hiv-Specific T Cell ImmunityNational Institute Of Allergy And Infectious Diseases2000–2001
- Human Cellular Immunity To Toxoplasma GondiiNational Institute Of Allergy And Infectious Diseases1997–1999
- Human Cellular Immunity To Toxoplasma GondiiNational Institute Of Allergy And Infectious Diseases1995–1996
- SCID Mouse And Human Stem Cell CoreNational Institute Of Allergy And Infectious Diseases1994–1995
- Cellular Immunity In AIDSNational Institute Of Allergy And Infectious Diseases1988–1989
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
